

VU Research Portal

The contribution of ABC transporters to dendritic cell development and function

van de Ven, R.

2009

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

van de Ven, R. (2009). *The contribution of ABC transporters to dendritic cell development and function*. [PhD-Thesis - Research and graduation internal, S.I.]. s.n.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl



Chapter 5

**Long-term doxorubicin exposure interferes with the differentiation of
Langerhans Cells from CD34+ precursor cells**

Submitted

Rieneke van de Ven

Anneke W. Reurs

Hetty J. Bontkes

Erik Hooijberg

Rik J. Scheper

George L. Scheffer

Tanja D. de Gruijl

Chapter 5

Abstract

As neoadjuvant and adjuvant chemotherapy schedules often consist of multiple treatment cycles over relatively long periods of time, it is important to know what effects protracted drug administration can have on the immune system. Here, we studied the long-term effects of doxorubicin on the capacity of dendritic cell (DC) precursors to differentiate into a DC subset, the Langerhans cells (LC). Precursor cells from the acute-myeloid leukemia-derived cell line MUTZ3 were stably transduced with human telomerase reverse transcriptase (hTERT) to facilitate their growth potential while preserving their unique capacity for cytokine-dependent DC and LC differentiation. These hTERT-MUTZ3 cells were selected with increasing concentrations of doxorubicin. Already after 1-2 months of selection with 30-90nM doxorubicin, the cells completely lost their capacity to differentiate into LC. This inhibition turned out to be reversible, as the cells slowly regained their capacity to differentiate after a 3-4 month drug-free period and with this became capable again of priming allogeneic T cells. Of note, the loss and gain of this capacity to differentiate coincided with the loss and gain of a subpopulation within the CD34⁺ proliferative compartment with surface expression of the stem cell factor receptor (SCF-R/CD117/c-Kit). These data are in favor of sufficiently long cytostatic drug-free intervals before applying autologous DC-based vaccination protocols, as specific DC precursors may need time to recover from protracted chemotherapy treatment and re-emerge among the circulating CD34⁺ haematopoietic stem and precursor cells.

Introduction

Recent therapeutic advances are turning cancer into a more chronic disease. With patients being treated on and off with cytotoxic drugs in order to control metastasis, the effects of such treatment on the immune system in the long run should be considered. Safeguarding the immune competence of cancer patients may be vital to their quality of life as well as overall survival. In addition, successful application of novel immunotherapies also requires intact immune effector functions. Dendritic cells (DC) are the main orchestrators of the immune system and have a key function in linking the innate with the adaptive immune response.¹ For autologous DC vaccination strategies, most often patient-derived material is used as a source of DC precursor cells. We therefore examined whether a long history of drug exposure could hamper DC differentiation.

The human acute myeloid leukemia (AML)-derived DC cell line MUTZ3² can develop into either interstitial DC (MUTZ3-IDC) by culturing the cells with granulocyte and macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor alpha (TNF α) and interleukin-4 (IL-4) or into Langerhans cells (MUTZ3-LC) by culturing the cells with GM-CSF, TNF α and transforming growth factor beta (TGF β).^{3,4} Of note, MUTZ-3 DC development accurately reflects all stages observed in its physiological CD34⁺ precursor-derived counterparts and as such this cell line presents a relevant and sustainable human DC/LC differentiation model.⁴ We recently found that short term exposure of CD34⁺ cells, including MUTZ-3, to the cytotoxic drugs mitoxantrone or doxorubicin induced accelerated DC and LC differentiation with corresponding functionalities like migration, allogeneic T cell stimulation and cytotoxic T lymphocyte (CTL) priming (van de Ven et al., manuscript in preparation). These observations support the use of single-dose cytostatic drugs, either as a local DC adjuvant or as a differentiating agent to facilitate *in vitro* DC culture for therapeutic purposes. In this study, we examined the effect of long-term drug exposure on the capacity of DC precursor cells to differentiate into functional LC. For these long-term cultures, we made use of MUTZ3 cells that had been stably transduced with the gene encoding the catalytic subunit of the telomerase complex, the human Telomerase Reverse Transcriptase (hTERT), in order to avoid replicative senescence and achieve high passage numbers with maintained cytokine-dependent

Long-term doxorubicin exposure interferes with the differentiation of LC from CD34+ precursor cells

differentiation ability. Derivation of this cell line for the first time allowed the *in vitro* study of the effects of truly long-term exposure of human precursor cells to cytostatic drugs on DC differentiation. Drug selection of these CD34⁺ DC precursors revealed that the selective loss of a SCF-R/c-KIT⁺ subpopulation resulted in an inability for LC differentiation. After removal of doxorubicin from the cultures this subpopulation re-emerged as did the LC differentiation capacity. The regained capacity to differentiate after drug removal, as well as the capacity of high passage hTERT-MUTZ3 cells to differentiate, rule out an hTERT-induced effect on LC differentiation. These data strongly suggest that a drug-free period of adequate length should be allowed for when autologous DC-based therapies are considered consecutive to chemotherapy, in order for the required precursors to recover.

Materials and methods

MUTZ3 and dendritic cell cultures:

The AML-derived MUTZ3 cell line was cultured as described before.³ In short, MUTZ3 progenitors were cultured in MEM- α (Minimum essential medium, Lonza, Vervier, Belgium) containing 20% fetal calf serum (FCS), 100 IU/ml sodium-penicillin, 100 μ g/ml streptomycin, 2 mM L-glutamine, 50 μ M β -mercaptoethanol (2ME) and 10% 5637 (renal cell carcinoma) conditioned medium (MUTZ3 routine medium) in 12-well plates (Costar) at a concentration of 0.2 million cells/ml and were passaged twice weekly. Langerhans cells (MUTZ3-LC) were cultured from MUTZ-3 progenitors with 10ng/ml TGF- β 1 (Biovision, Mountain View, CA), 1000 IU/ml rhGM-CSF (Sagramostim, Berlex), and 120 IU/ml TNF α (Strathmann Biotec) for 10 days to obtain immature MUTZ3-LC as described previously.⁵ Immature MUTZ3-LC were matured by adding 33% monocyte condition medium (MCM) and 2400 IU/ml TNF α for 48 hours.

Retroviral constructs:

The retroviral vector LZRS-hTERT-IRES- Δ NGFR has been described previously.⁶ The Δ NGFR is a truncated form of the receptor, with no signaling moiety. Retroviruses were propagated in Phoenix A cells by plasmid DNA transfection using Lipofectamin 2000 (Invitrogen) in serum free medium for 3 hours. Medium was refreshed after 24 hours and viral supernatants were harvested 48 hours post transfection and were either directly used for transduction or stored at -80°C in 0.5 ml aliquots.

MUTZ3 retroviral transduction

For the generation of MUTZ3 cells expressing hTERT, MUTZ3 progenitor cells were transduced with the LZRS-hTERT-IRES- Δ NGFR retrovirus as described before.^{6,7} In short, 0.5 million MUTZ3 progenitor cells were transferred to fibronectin-coated (40 μ g/ml RetroNectin, Takara, Japan) non-tissue culture coated plates (BD Biosciences, Heidelberg, Germany) in 0.5 ml viral supernatant supplemented with 10% 5637 conditioned medium. Plates were centrifuged for 90 minutes at 2000rpm at 25°C. Cells were re-transduced with 0.5 ml fresh viral supernatant after 24 hours. The retrovirus infected and transduced the CD34⁺ proliferative progenitor population of the MUTZ3 cell line. hTERT-MUTZ3 cells were obtained by selecting the NGFR-positive cells by flow sorting and cells were maintained in MUTZ3 routine medium as described above. Doxorubicin selection was started by culturing the hTERT-MUTZ3 cells with 5nM doxorubicin (Amersham Pharmacia, Roosendaal, The Netherlands). Cells were passaged twice weekly as described above. Drug concentrations were gradually increased up to 120nM. Differentiation analysis were performed at different time points during selection with 30nM (dox30+) and 90nM (dox90+) cells. Control, non-exposed hTERT-MUTZ3 cells were kept in culture alongside the drug-selected cells and were tested for their differentiating capacity using cells with the same passage numbers.

hTERT PCR

RNA was isolated using RNA-Bee (Bio-connect, Huissen, The Netherlands), following manufacturer's guidelines. The RNA concentration was determined on a Nanodrop spectrophotometer. cDNA synthesis and PCR reaction were essentially as described before and were performed with 200ng RNA.^{8,9} Primers and probes for hTERT and the household control gene U1 small nuclear ribonucleoprotein specific A protein (SnRNP U1A) were as described previously.⁹ hTERT forward 5' \rightarrow 3' primer: GAAGGCACTGTTTCAGCGTGCTCAAC; hTERT reverse 5' \rightarrow 3' primer: GGGTTGATGATGCTGGCGATGACC; hTERT probe:

Chapter 5

GGCGCCTGAGCTGACTTTGTCAAGGTGGA. SnRNP U1A forward 5'→3' primer: CAGTATGCCAAGACCGACTCAGA ; snRNP U1A reverse 5'→3' primer: GGCCCGGCATGTGGTGCATAA; snRNP U1A probe: AGAAGAGGAAGCCCAAGAGCCA. The RT-PCR reaction was performed at 35 cycles.

XTT cytotoxicity assay

20.000 cells were seeded per well in 96-well round-bottom plates in a volume of 50µl per well in culture medium. Doxorubicin was diluted to a maximum concentration of 300nM in culture medium and 1:3 diluted to 120 pM. 50ul diluted doxorubicin was added per well in triplicate for each concentration, giving rise to a doxorubicin range from 0.06-150nM. Cells were exposed to the drugs for 96 hours. Cell viability was measured by adding XTT supplemented with phenazine methosulphate (PMS) for 2-4 hours, after which optical density was measured at 450nm. Cell viability was determined relative to the control cells to which no doxorubicin had been added.

Flow cytometry

LC were immunophenotyped using FITC- and /or PE-conjugated Mabs directed against: CD1a (1:25), CD54 (1:25), CD80 (1:25), CD86 (1:25), CD40 (1:10) (PharMingen, San Diego, CA), CD14 (1:25), HLA-DR (1:25), DC-SIGN (1:10) (BD Biosciences, San Jose, CA), CD83 (1:10), CD34 (1:10), Langerin (1:10) (Immunotech, Marseille, France). hTERT MUTZ3 cells, dox90+ and dox90- cells were phenotyped for cytokine receptors using the following antibodies: CD34-APC, CD116-FITC, CD117-PE (PharMingen, San Diego, CA), CD14-PerCP_Cy5, and CD123-PE (BD Biosciences, San Jose, CA). In short, 2.5 to 5·10⁴ cells were washed in PBS supplemented with 0.1% BSA and 0.02% NaN₃ and incubated with specific or corresponding isotype-matched control Mabs for 30 minutes at 4°C. Cells were washed and analyzed with a FACS-Calibur flow cytometer (Becton and Dickinson, San Jose, CA) equipped with CellQuest analysis software and the results were expressed as mean or median fluorescence intensities, the percentage of positive cells or the relative ratios of positive cells compared to the control cultures.

Mixed Leukocyte Reaction (MLR)

MLR was performed as described.⁵ In short, 1·10² - 3·10⁴ LC were co-cultured with 1·10⁵ allogeneic peripheral blood lymphocytes for 4 days in 96-wells plates in IMDM containing 10% human pooled serum (HPS) (Sanquin, Amsterdam, The Netherlands), 100 IU/ml sodium-penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 50 µM β-mercaptoethanol. At day 4, 2.5µCi/ml [³H]-thymidine (6.7Ci/mmol, MP Biomedicals, Irvine, CA) was added per well for 16 hours. Plates were harvested onto glass fiber filtermats (Packard Instruments, Groningen, The Netherlands) using a Skatron cell harvester (Skatron Instruments, Norway), and [³H]-thymidine incorporation was quantified using a Topcount NXT Microbetacounter (Packard, Meriden, CT).

Statistical analysis

Statistical analysis of the data was performed using the paired or unpaired two-tailed Student's T-test. Differences were considered statistically significant when p<0.05.

Results

Doxorubicin selection of MUTZ3 cells

The anthracyclin doxorubicin was chosen as a selection drug to study the effects of long-term drug exposure on DC precursor cells, because of its high clinical relevance. Doxorubicin is widely used to treat a variety of cancer types, mostly in combination with other cytotoxic drugs, as in CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) regimens.¹⁰⁻¹⁴ As a source of DC precursor cells, we made use of the MUTZ3 cell line², which can be differentiated into either interstitial DC or LC.^{3,4} The IC₅₀ value of doxorubicin in MUTZ3 cells was determined by means of a XTT cytotoxicity assay (IC₅₀: 29 ± 18.3 nM (n=3)). Although the cells could be cultured in the presence of doxorubicin up to a concentration of 30nM, the selected cells displayed marginal resistance to the drug compared to the parent MUTZ3 cells when

Long-term doxorubicin exposure interferes with the differentiation of LC from CD34+ precursor cells

analyzed in a cytotoxicity test (data not shown) and the 30nM-selected cells already lost their proliferative capacity after 9 passages. As a consequence, increasing the concentration of doxorubicin, in order to generate a drug-resistant cell line did not prove feasible.




Figure 1: Telomerase expression and doxorubicin sensitivity of MUTZ3 and hTERT-MUTZ3 cells.

A) MUTZ3 progenitors and hTERT-MUTZ3 progenitors were analyzed for telomerase expression by RT-PCR. **B)** MUTZ3 and hTERT-MUTZ3 progenitors were analyzed for their sensitivity to the anthracyclin doxorubicin by means of a XTT assay over 96 hours (experiment representative of 3).

The telomerase complex plays a vital role in preventing replicative senescence. Of note, wtMUTZ3 cells were found to lack expression of hTERT mRNA [Figure 1A], which might have contributed to the failure to generate a continuously proliferating, doxorubicin resistant MUTZ3 cell line. We therefore generated MUTZ3 progenitor cells stably expressing hTERT via transduction with a retroviral construct encoding hTERT (designated hTERT-MUTZ3). The presence of hTERT within these cells [Figure 1A] allowed for prolonged culture (and hence longer drug exposure time) while maintaining their dependence on exogenous cytokines for growth, which is a typical feature of the MUTZ3 cell line.^{2,15}




Figure 2. Effects of hTERT introduction on MUTZ3-LC differentiation and proliferation.

A) Dotplots of flow cytometric analysis for the LC-typifying markers CD1a and Langerin on immature LC (iLC) cultures from MUTZ3 (iLC; left) and hTERT-MUTZ3 (hT-iLC; right). **B)** Average percentages (+ standard deviation) of CD14⁺, CD34⁺, CD1a⁺ and Langerin⁺ cells within iLC cultures from MUTZ3 or hTERT-MUTZ3 cells (n=3). **C)** Progenitor cell proliferation in the presence of 30nM doxorubicin. Shown are the passage numbers against the expansion of the progenitor cells. MUTZ3 progenitor cells stopped proliferating after 9 passages in the presence of 30nM doxorubicin, whereas hTERT-MUTZ3 cells could be cultured for over 160 passages (shown are the details up to passage 50).

Chapter 5

Introduction of hTERT into MUTZ3 precursor cells did not influence the sensitivity of the cells for doxorubicin [Figure 1B], but did enhance their proliferation rate compared to non-transduced MUTZ3 cells (average expansion factor over 3 days 7.8 ± 1.3 and 5.7 ± 1.7 for hTERT-MUTZ3 and MUTZ3, respectively ($p < 0.02$), averaged over 8 consecutive passages). hTERT-MUTZ3 cells retained their ability to differentiate into CD1a⁺ Langerin⁺ LC [Figure 2A and 2B]. Figure 2C shows the proliferation rate (i.e. expansion factor over the course of 3 days) of MUTZ3 versus hTERT-MUTZ3 upon 30nM doxorubicin selection. Whereas the MUTZ3 cells stopped proliferating after 9 passages, the hTERT-MUTZ3 cells maintained a relatively consistent proliferation rate on drug-selection for over 160 passages (data shown for the first 50 passages). Of note, wtMUTZ3 cells generally display a considerable fluctuation in expansion factors between passages. The same variable pattern was observed in the hTERT-MUTZ3 cells [Figure 2C].

Doxorubicin selection hampers LC differentiation

Doxorubicin concentrations were gradually increased, from 5 and 10nM (Passage (P)22) up to 20nM (P30), 30nM (P55) (dox30+), and 90nM (P67) (dox90+). The cells were analyzed for their sensitivity to doxorubicin and their LC differentiation capacity. Dox30+ cells were 2-fold and dox90+ cells were 8-fold more resistant to doxorubicin compared to unselected hTERT-MUTZ3 cells (measured by XTT with P122 and P167). Culturing the cells under doxorubicin selection significantly affected their expansion factors, which were 7.3 ± 1.7 for unselected hTERT-MUTZ3, 5.0 ± 2.0 for dox30+ and 1.2 ± 2.0 for dox90+ (averaged over 13 passages) ($p < 0.02$ for both dox30+ and dox90+). LC differentiation from dox30+ and dox90+ cells was carried out in the absence of doxorubicin and the non-exposed hTERT-MUTZ3 control cells were always differentiated from the same passage number as the drug-exposed dox30+ and dox90+ cells. Figure 3 shows that selection of hTERT-MUTZ3 progenitor cells with doxorubicin drastically reduced the capacity of the cells to differentiate into LC, reflected by significantly reduced levels of the LC-typifying markers CD1a and Langerin, as well as of the co-stimulatory markers CD40 and CD86 and of HLA-DR (n=3; differentiation induced at P73, P83 and P189, data shown for dox 90+ cells; similar results were obtained with the dox30+ cells [data not shown]).




Figure 3. Doxorubicin selection of progenitor cells hampers LC differentiation.

hTERT-MUTZ3 and dox90+ hTERT-MUTZ3 cells were differentiated into immature LC following standard culture protocol and were analyzed for phenotypic marker expression by flow cytometry on day 10. Shown are the percentages of CD1a⁺ (top left), Langerin⁺ (top middle) and CD40⁺ (top right) cells and the mean fluorescence intensity levels of CD86 (bottom left), CD54 (bottom middle) and HLA-DR (bottom right) in both the hTERT-MUTZ3 and dox90+ LC cultures (n=3, $p < 0.05$).

Long-term doxorubicin exposure interferes with the differentiation of LC from CD34+ precursor cells




Figure 4. Doxorubicin-induced suppression of LC differentiation is reversible.

hTERT-MUTZ3 cells, dox90+ cells and dox90- cells (drug free) were differentiated into immature LC for 10 days after 1 month, 3 months and 4 months of drug-depletion of the dox90- cells. a) dotplots showing CD1a and Langerin expression on hT iLC, dox90+ iLC and dox90- iLC. Upon a drug free period of at least 3 months, the dox90- cells regained their differentiating potential. b) Percentages of cells expressing the DC maturation marker CD83 in cultures started 1 month, 3 months and 4 months after drug depletion of the dox90- cells. c) MLR were performed using hT-mLC, dox90+ mLC and dox90- mLC (depleted from drugs for 1 month (left), 3 months (middle) and 4 months (right)), to analyze the T cell stimulating capacities of the mLC.

Inhibition of LC differentiation by doxorubicin selection is reversible

Dox90+ cells were next cultured in the absence of doxorubicin to study whether the doxorubicin-induced inability to differentiate into LC could be reversed. LC differentiation was analyzed after 1, 3, and 4 months of drug deprivation. Subsequent to differentiation, maturation was induced by addition of a cytokine cocktail and after two days the capacity of the matured cells to stimulate T cell proliferation in an alloMLR was determined. Figure 4A shows dot plots with percentages of CD1a and Langerin positive cells on iLC cultured from the different cell passages at the indicated time points (P128, P145 and P160 for 1, 3 and 4 months, respectively). The differentiation capacity of the cells selected with 90nM doxorubicin gradually returned after 3 months of drug depletion [dox90- LC, Figure 4A]. The differentiated drug-depleted cells also responded to maturation stimuli, reflected by the increase in the percentage of cells expressing the maturation marker CD83 [Figure 4B]. Accordingly, their ability to stimulate T cell proliferation in an alloMLR also improved. After 3 and 4 months in the absence of drugs, dox90- mLC showed enhanced T cell stimulatory abilities compared to their continuously drug-selected counterparts and after 4 months of drug deprivation their T cell stimulatory capacity even matched that of the parental (passage-matched) hTERT-mLC [Figure 4C].

Capacity to differentiate coincides with the expression of the SCF-R

As hTERT-MUTZ3 cells remained dependent on exogenous cytokines for their growth and differentiation, we studied the expression of cytokine receptors involved in these processes on the drug-selected and subsequently

Chapter 5

drug-deprived cells, as well as on their unselected, parental counterparts. As the percentages of CD14⁺ cells within all cultures was less than five percent, we focused on the expression of cytokine receptors on the proliferative CD34⁺ cells. All CD34⁺ cells within all three cultures expressed high levels of the IL-3 receptor (CD123), low levels of the GM-CSF receptor (CD116, 5% positive) and TNF receptors I and II (5% positive) and were negative for the IL-6 receptor (CD126) (data not shown). There was, however, a striking difference in the expression of the stem cell factor receptor (SCF-R / CD117 / *c-kit*) [Figure 5]. While 36% of the parental hTERT-MUTZ3 CD34⁺ population expressed the SCF-R, expression of SCF-R was completely lost in the doxorubicin-selected cells. Of note, CD34⁺ dox90- cells again displayed normalized SCF-R expression levels, comparable to the parental hTERT-MUTZ3 cells [Figure 5].




Figure 5. Doxorubicin exposure down-regulates SCF-R/c-Kit expression on CD34⁺ progenitor population.

hTERT-MUTZ3, dox90+ and dox90- (4 months drug free) progenitor cells were analyzed for the expression of the SCF-R/c-Kit. Continuous exposure to doxorubicin abrogated expression of SCF-R/c-Kit on a subset of CD34⁺ progenitors. SCF-R/c-Kit expression returned upon drug depletion.

Discussion

This study describes a possible consequence of long-term cytostatic drug exposure of DC precursor cells. By making use of the hTERT-transduced MUTZ3 cell line, we have demonstrated that prolonged doxorubicin exposure renders CD34⁺ precursor cells irresponsive to LC-differentiating cytokines. Fortunately, this detrimental effect of doxorubicin on the differentiation capacity of DC precursors proved to be a reversible phenomenon. The cells regained the capacity to differentiate and consequently their capacity to stimulate T cell proliferation, after a 3-4 month drug-free period. Analysis of cytokine receptor expression patterns on unexposed hTERT-MUTZ3 cells, doxorubicin-exposed dox90+ hTERT-MUTZ3 cells and the dox90- hTERT-MUTZ3 cells that had been drug-free for 4 months, revealed altered expression of the SCF-R (CD117/*c-kit*). Whereas a subpopulation of CD34⁺ hTERT-MUTZ3 cells expressed this receptor, a SCF-R expressing population was absent in the doxorubicin-selected cells. Interestingly, when deprived of doxorubicin, in conjunction with the regained ability to differentiate, the SCF-R⁺CD34⁺ precursor population re-emerged. It has been reported that SCF, the ligand for the SCF-R, in combination with FLT3-ligand, is crucial for the maintenance of a long-term proliferative pool of CD34⁺ DC precursor cells.¹⁶ While blockade of the SCF-R did not inhibit DC differentiation from CD34⁺ precursors, it did interfere with continued proliferation of a subset of CD34⁺ precursors with the ability to differentiate into DC. Hence, the observation that the dox90+ cells lack this SCF-R⁺ subpopulation and simultaneously have lost their ability to differentiate, suggests that, due to chronic doxorubicin exposure, this DC precursor subset with long-term proliferative potential is selectively depleted from the general precursor population. A similar effect could be expected on the DC precursor cells among the circulating haematopoietic stem and precursor cells (HSPC) in patients treated with this drug and perhaps with related drugs. Research in patient groups treated with doxorubicin, or related drugs, should be considered, to gain more insight into the effects of repetitive

Long-term doxorubicin exposure interferes with the differentiation of LC from CD34⁺ precursor cells

chemotherapy treatment on the presence and quality of DC precursor cells *in vivo*, in order to determine whether longer drug-free intervals should be considered when applying chemotherapy regimens prior to DC-based immunotherapies. In this regard, the use of allogeneic rather than autologous DC vaccines should also be further explored for patients with a long history of chemotherapy treatment.¹⁷

One could argue that the altered differentiation capacity could be caused by the presence of hTERT in the MUTZ3 cells, which could lead to chromosomal instability and hence an altered differentiation potential.¹⁸ However, it has been shown that hTERT-transduced T cells can be kept in culture for many months, without losing their antigen specificity or their cytotoxic abilities.¹⁹ Furthermore, in our studies, non-drug exposed hTERT-MUTZ3 cells were kept in culture alongside the drug-selected cells and were used as controls in the differentiation studies. Despite the continuous expression of hTERT, these cells maintained their cytokine dependence for growth and were still capable of LC differentiation at high passage numbers. Also, the observation that the drug-induced differentiation defect, along with SCF-R/c-*kit* expression on CD34⁺ cells, could be reversed upon withdrawal of the drug is additional proof that the observed effects are hTERT independent.

The negative effects of long-term exposure of DC precursor cells to cytostatic drugs are in sharp contrast with our own observation that a single low dose of the anthracyclin doxorubicin, or the related anthracenedione mitoxantrone, at the start of *in vitro* DC differentiation from CD34⁺ precursor cells strongly promotes and even accelerates differentiation (van de Ven et al., manuscript in preparation). Also, work by Zitvogel *et al.* has shown that systemic doxorubicin treatment can promote anti-tumor responses due to the release of danger signals like the high mobility group box 1 protein (HMGB1) released from dying tumor cells. Release of HMGB1 acts as a maturation signal for resident DC and promotes tumor antigen presentation to CD8⁺ T cells.²⁰⁻²² This notwithstanding, our data imply that in the long run, repetitive systemic treatment with cytostatic drugs could be disadvantageous due to its negative effect on the expansion of CD34⁺c-*kit*⁺ DC precursor cells.

It is known that cytostatic drugs can induce expression of ATP-binding cassette (ABC) transporters like P-glycoprotein (P-gp; ABCB1), Multidrug resistance protein 1 (MRP1; ABCC1) or the breast cancer resistance protein (BCRP; ABCG2), thereby inducing multidrug resistance in tumor cells.^{23,24} As the protein expression levels of these ABC transporters were unaltered on doxorubicin-selected cells (data not shown), the effect of progenitor cell selection with doxorubicin seems ABC transporter independent, and seems mainly to be caused by the loss of SCF-R/c-*kit* expression on proliferating CD34⁺ DC precursor cells. Altogether our data suggest that, if feasible, sufficiently long drug-free intervals should be included in chemotherapy regimens in order to allow the immune system to recuperate. In addition, when DC vaccination is being considered, patients with a long history of chemotherapy treatment should be tested for their suitability for autologous DC vaccination strategies, as their DC precursor cells might give rise to DC of poor quality. These patients might benefit more from allogeneic DC vaccination approaches as recently reviewed by us.¹⁷

Acknowledgements

The authors would like to thank Drs. J. de Wilde (VU University medical center, Amsterdam) for her help with the hTERT RT-PCR. This work was supported by a grant from the Dutch Cancer Society (KWF) to R.J.S., G.L.S. and T.D.G. (KWF2003-2830).

Disclosures

The authors have no financial conflict of interest.

Reference List

- (1) Ueno H, Klechevsky E, Morita R et al. Dendritic cell subsets in health and disease. *Immunol Rev.* 2007;219:118-142.

Chapter 5

- (2) Hu ZB, Ma W, Zaborski M et al. Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3. *Leukemia*. 1996;10:1025-1040.
- (3) Masterson AJ, Sombroek CC, de Gruijl TD et al. MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. *Blood*. 2002;100:701-703.
- (4) Santeogoets SJ, Masterson AJ, van der Sluis PC et al. A CD34+ human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+CD11b+ Langerhans cell precursor. *J Leukoc Biol*. 2006;80:1337-1344.
- (5) van de Ven R, de Jong MC, Reurs AW et al. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. *J Immunol*. 2006;176:5191-5198.
- (6) Schreurs MW, Scholten KB, Kueter EW et al. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. *J Immunol*. 2003;171:2912-2921.
- (7) Bontkes HJ, Ruizendaal JJ, Kramer D et al. Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells. *J Immunother*. 2006;29:188-200.
- (8) Bijl J, van Oostveen JW, Kreike M et al. Expression of HOXC4, HOXC5, and HOXC6 in human lymphoid cell lines, leukemias, and benign and malignant lymphoid tissue. *Blood*. 1996;87:1737-1745.
- (9) Snijders PJ, van Duin M, Walboomers JM et al. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. *Cancer Res*. 1998;58:3812-3818.
- (10) Long HJ, III, Rayson S, Podratz KC et al. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature. *Am J Clin Oncol*. 2002;25:547-551.
- (11) Dowdy SC, Boardman CH, Wilson TO et al. Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer. *Am J Obstet Gynecol*. 2002;186:1167-1173.
- (12) Long HJ, III, Monk BJ, Huang HQ et al. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. *Gynecol Oncol*. 2006;100:537-543.
- (13) von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPAR DUO study of the German Breast Group. *J Clin Oncol*. 2005;23:2676-2685.
- (14) von Minckwitz G, Jonat W, Fasching P et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. *Breast Cancer Res Treat*. 2005;89:165-172.
- (15) Santeogoets SJ, van den Eertwegh AJ, van de Loosdrecht AA, Scheper RJ, de Gruijl TD. Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. *J Leukoc Biol*. 2008.
- (16) Curti A, Fogli M, Ratta M, Tura S, Lemoli RM. Stem cell factor and FLT3-ligand are strictly required to sustain the long-term expansion of primitive CD34+DR- dendritic cell precursors. *J Immunol*. 2001;166:848-854.
- (17) de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. *Cancer Immunol Immunother*. 2008;57:1569-1577.
- (18) Schreurs MW, Hermsen MA, Geltink RI et al. Genomic stability and functional activity may be lost in telomerase-transduced human CD8+ T lymphocytes. *Blood*. 2005;106:2663-2670.
- (19) Andersen H, Barsov EV, Trivett MT et al. Transduction with human telomerase reverse transcriptase immortalizes a rhesus macaque CD8+ T cell clone with maintenance of surface marker phenotype and function. *AIDS Res Hum Retroviruses*. 2007;23:456-465.
- (20) Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. *J Exp Med*. 2005;202:1691-1701.
- (21) Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. *Nat Med*. 2007;13:1050-1059.
- (22) Ullrich E, Menard C, Flament C et al. Dendritic cells and innate defense against tumor cells. *Cytokine Growth Factor Rev*. 2008;19:79-92.
- (23) Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. *Oncologist*. 2003;8:411-424.
- (24) Annereau JP, Szakacs G, Tucker CJ et al. Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. *Mol Pharmacol*. 2004;66:1397-1405.